Viking Therapeutics Posts Wider Q2 Loss

Viking Therapeutics (VKTX) reported a wider-than-expected GAAP net loss of $(0.58) per share for Q2 2025, primarily due to a significant increase in research and development expenses to $60.2 million as the company scaled up late-stage clinical trials for its lead obesity drug candidate, VK2735. Despite the elevated cash burn, VKTX maintained substantial liquidity with $808 million in cash and short-term investments, supporting its ongoing large clinical programs. The company's immediate focus remains on key clinical readouts, particularly top-line results from its oral VK2735 VENTURE trial in H2 2025, which are critical amidst strong competition in the obesity market.

Analysis

Viking Therapeutics' Q2 2025 results highlight a company in a critical, capital-intensive phase of its development, defined by escalating investment in its late-stage pipeline. The company reported a net loss per share of $(0.58), missing consensus estimates of $(0.45) by a significant 29.1%. This wider loss was directly attributable to a 152.9% year-over-year increase in research and development expenses, which reached $60.2 million as the company scaled up large, pivotal trials for its lead obesity candidate, VK2735. Despite the increased cash burn, the company maintains a robust liquidity position with $808 million in cash and short-term investments, providing a sufficient runway to fund operations through key upcoming milestones. The report underscores that the investment thesis is not about current profitability but about future potential, with the company's value hinging on successful clinical outcomes for VK2735 against formidable competitors like Novo Nordisk and Eli Lilly. The lack of forward financial guidance appropriately shifts focus to the primary upcoming catalyst: the top-line data from the Phase 2 oral VK2735 trial expected in the second half of 2025, which will be a pivotal event for the company.

Key Decisions for Investors

• Investors should view the earnings miss as a secondary concern to pipeline progress, as the investment case for VKTX is almost entirely dependent on future clinical trial data, not near-term financials.
• The upcoming top-line results from the VENTURE-Oral study in H2 2025 represent the most significant near-term catalyst; a long position is a bet on a positive outcome, while any negative data would severely impact the stock's valuation.
• Monitor the quarterly cash burn rate against the $808 million reserve, as continued large-scale trial spending could accelerate the need for future dilutive financing ahead of any potential revenue generation.
• Evaluate any clinical data from VK2735 not in isolation, but directly against the efficacy and safety benchmarks set by established market leaders Eli Lilly and Novo Nordisk to gauge its true commercial potential.